CINECA IRIS Institutional Research Information System

SAGLIO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.866
EU - Europa 13.207
AS - Asia 5.878
AF - Africa 136
SA - Sud America 86
OC - Oceania 69
Continente sconosciuto - Info sul continente non disponibili 19
Totale 37.261
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.593
CN - Cina 3.890
IT - Italia 2.570
IE - Irlanda 2.140
SE - Svezia 1.488
UA - Ucraina 1.331
DE - Germania 1.330
FR - Francia 1.189
FI - Finlandia 910
KR - Corea 783
GB - Regno Unito 497
VN - Vietnam 425
PL - Polonia 419
DK - Danimarca 352
AT - Austria 322
JP - Giappone 252
CA - Canada 244
BE - Belgio 203
IN - India 162
NL - Olanda 84
ES - Italia 64
HK - Hong Kong 62
AU - Australia 59
RO - Romania 51
IR - Iran 47
SN - Senegal 46
TR - Turchia 44
CH - Svizzera 39
RU - Federazione Russa 39
GR - Grecia 38
BR - Brasile 37
LB - Libano 36
PT - Portogallo 28
TW - Taiwan 28
CZ - Repubblica Ceca 24
MU - Mauritius 22
NO - Norvegia 22
PK - Pakistan 21
SG - Singapore 20
AR - Argentina 19
EU - Europa 18
IL - Israele 18
MX - Messico 18
EG - Egitto 17
NG - Nigeria 16
ZA - Sudafrica 16
MY - Malesia 14
BG - Bulgaria 13
UZ - Uzbekistan 13
CL - Cile 12
CO - Colombia 11
ID - Indonesia 10
NZ - Nuova Zelanda 10
IQ - Iraq 9
TH - Thailandia 9
HR - Croazia 8
HU - Ungheria 8
PH - Filippine 8
SA - Arabia Saudita 8
SI - Slovenia 8
LU - Lussemburgo 7
PR - Porto Rico 6
SK - Slovacchia (Repubblica Slovacca) 6
KE - Kenya 4
MA - Marocco 4
RS - Serbia 4
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
DZ - Algeria 3
JO - Giordania 3
MK - Macedonia 3
PE - Perù 3
BD - Bangladesh 2
BT - Bhutan 2
BY - Bielorussia 2
ET - Etiopia 2
LI - Liechtenstein 2
LK - Sri Lanka 2
MO - Macao, regione amministrativa speciale della Cina 2
MT - Malta 2
TN - Tunisia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EE - Estonia 1
GT - Guatemala 1
LV - Lettonia 1
MW - Malawi 1
QA - Qatar 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
Totale 37.261
Salva come PNG Salva come JPEG
Città #
Beijing 2.781
Chandler 2.533
Dublin 2.126
Ann Arbor 1.250
Houston 1.170
Fairfield 1.151
Villeurbanne 859
Jacksonville 740
Torino 675
Wilmington 660
Medford 654
Princeton 635
Woodbridge 603
Dearborn 573
Ashburn 487
Seattle 475
Nyköping 466
Warsaw 404
Cambridge 391
Vienna 312
Fremont 278
Pisa 265
Boston 255
Dong Ket 235
Milan 195
Redwood City 191
Düsseldorf 181
Brussels 179
San Mateo 176
Nanjing 132
Boardman 126
Toronto 116
Turin 114
Verona 102
Hangzhou 84
Hefei 82
Norwalk 79
Hebei 73
Washington 69
San Diego 67
Shanghai 63
Frankfurt am Main 61
Guangzhou 61
Lachine 56
Falls Church 47
Des Moines 45
Philadelphia 45
Tokyo 45
Munich 43
Mountain View 41
Phoenix 38
Rome 38
Wuhan 38
Kunming 37
Padova 37
San Jose 37
Chongqing 36
Jinan 36
Ottawa 35
Zhengzhou 34
Shenyang 30
Nanchang 29
Chengdu 27
Horia 26
Seoul 25
Bologna 24
Taipei 24
Changsha 23
Dallas 23
Fuzhou 23
Central District 22
Napoli 22
Silver Spring 22
Redmond 21
Xian 21
Nürnberg 20
New York 18
Nijmegen 18
Upper Marlboro 18
Duncan 17
Paris 17
Tianjin 17
Abuja 16
Chennai 16
Florence 16
Sezze 16
São Paulo 16
Changchun 15
Piemonte 15
Vestignè 15
Istanbul 14
Alpignano 13
Dresden 13
Buffalo 12
Hyderabad 12
London 12
Glen Burnie 11
Heidelberg 11
Nutley 11
Salt Lake City 11
Totale 23.549
Salva come PNG Salva come JPEG
Nome #
Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy 583
Morgana acts as an oncosuppressor in chronic myeloid leukemia. 413
A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. 368
Nuovi inibitori della diidroorotato deidrogenasi umana (hDHODH) e loro uso mirato sul differenziamento mieloide 367
Comparison of 3 Tfr2-deficient murine models suggestsdistinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues 340
Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones 312
A comparative study of myocardial molecular phenotypes of two tfr2β null mice: Role in ischemia/reperfusion 278
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 257
NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION 248
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 240
Two novel mutations in the tmprss6 gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form 225
Morgana is a new oncosuppressor in CML 221
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 219
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 212
Non-Oncogene Addiction to BRD in CLL: from JQ1 Response to Resistence 196
Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes 194
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. 188
Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population 187
Analysis of microsatellite instability in chronic lymphoproliferative disorders 186
THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 172
Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH 170
Development of cellular and humoral response against WT1 protein vaccination in mice 167
The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias 167
BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation 166
BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia. 165
Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis 165
New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia 165
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034 164
Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party. 163
PHARMACOGENETIC DETERMINANTS OF PLASMATIC AND INTRACELLULAR TYROSINE KINASE INHIBITORS 161
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 160
The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy 160
Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature 160
A novel assay to detect calreticulin mutations in myeloproliferative neoplasms 157
Transferrin Receptor 2 Dependent Alterations of Brain Iron Metabolism Affect Anxiety Circuits in the Mouse 154
Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia 152
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 149
A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML. 148
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 146
Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms 144
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study 143
ERYTHROFERRONE EXPRESSION LEVELS IN MYELODYSPLATIC SYNDROMES SHOW CLINICAL RELEVANCE 143
Present results and future perspectives in optimizing chronic myeloid leukemia therapy 142
Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection 141
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily 140
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 137
Role of Cytochrome P450 in imatinib pharmacokinetics: clinical relevance of inhibitors/inducers concomitant use 136
Genetic Screening for Potential New Targets in Chronic Myeloid Leukemia Based on Drosophila Transgenic for Human BCR-ABL1 136
Nilotinib in the treatment of chronic myeloid leukemia 135
Deferasirox-dependent iron chelation enhances mitochondrial dysfunction and restores p53 signaling by stabilization of p53 family members in leukemic cells 134
Early prediction of treatment outcome in acute myeloid leukemia by measurment of WT1 transcript levels in peripheral blood samples collected after chemotherapy 131
The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice 130
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice 130
A new BCR-ABL1 Drosophila model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia 130
The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia 129
Role of cytochrome P450 in imatinib pharmacokinetics: clinical relevance of inhibitors/inducers concomitant use 126
Characterization of human mitochondrial ferritin promoter: Identification of transcription factors and evidences of epigenetic control 123
Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib 121
DROPLED DIGITAL PCR MAY HAVE A PROGNOSTIC VALUE FOR PREDICTING RELAPSE AFTER IMATINIB DISCONTINUATION 120
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 119
Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex 115
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report 114
Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells 114
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias 114
A very sensitive and rapid method for BCR-ABL T315Imutation detection by peptide nucleic acid directed PCR clamping 113
A new non canonical role of IkB-alpha in chronic myleoid leukemia pathogenesis 111
Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study 110
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR 110
INHIBITION OF USP7 INDUCES SELECTIVE CANCER CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PTEN AND INDEPENDENTLY FROM P53 STATUS 109
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia 109
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 108
A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics 108
NEW ALTERNATIVE PROTEIN Bcr/Abl-OOF SHOWS ONCOGENIC ACTIVITY BY ACTIVATION OF RAC AND COOPERATION WITH Bcr/Abl IN CHRONIC MYELOID LEUKEMIA. 106
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 106
Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion. 105
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase 104
COMPARISON OF DROPLET DIGITAL PCR AND STANDARD PCR IN CHRONIC MYELOID LEUKEMIA PATIENTS IN MR4 104
A human leukemic T-cell line bears an abnormal and overexpressed c-myc gene: molecular and functional characterization of the rearrangement. 103
ANALYSIS OF IRON METABOLISM IN TFR2 TARGETED ANIMALS BRAIN 103
Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients 102
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 100
Adhesion of polymorphonuclear cells to endothelial cells is physiologically inhibited by Gas6 99
The choice of first-line chronic myelogenous leukemia treatment 99
A 3' truncation of MYC caused by chromosomal translocation in a human T-cell leukemia increases mRNA stability. 99
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 98
ALTERNATIVE SPLICING VARIANT COULD BE RESPONSIBLE OF MORGANA UNDER-EXPRESSION IN ACML 97
TFR2 AND EpoR EXPRESSION AT DIAGNOSIS AS POSSIBLE PREDICTORS OF ERYTHROPOIETIN TREATMENT RESPONSE IN MDS PATIENTS 97
The AKT/mTOR/P70S6K/4EB-P1 Signaling Pathway Is Activated in a Subset of Multiple Myeloma Patients and Correlates with High Serum Levels of Beta 2-Microglobulin. 96
Effects of erythropoiesis-stimulating agents on overall survival of international prognostic scoring system low/intermediate-1 risk, transfusion-inde-pendent myelodysplastic syndrome patients: A cohort study 96
Nanocarriers as magic bullets in the treatment of leukemia 96
Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR? 95
Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia 95
4-hydroxynonenal specifically inhibits c-myb but does not affect c-fos expressions in HL-60 cells. 94
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion 93
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 93
Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells 93
ROCK AS THERAPEUTICAL TARGET FOR MORGANA LOW CML 91
Inhibition OF USP7 Induces Selective Cancer Cell Death in Chronic Lymphocytic Leukemia 90
The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. 90
Design and Application of a Novel PNA Probe for the Detection At a Single Cell Level of BCR-ABL T315I Mutation in Chronic Myeloid Leukemia Patients 89
Totale 15.303
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.252
article - articoli 0
book - libri 0
conference - conferenze 23.611
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.863
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.634 0 0 155 125 111 229 85 362 111 295 871 290
2019/20205.841 200 168 267 704 425 977 680 454 590 589 413 374
2020/20215.527 446 403 408 323 581 324 484 229 581 393 541 814
2021/20226.098 259 360 275 488 257 227 509 353 220 584 1.137 1.429
2022/20238.274 955 621 218 713 697 2.200 790 489 751 203 415 222
2023/20241.274 502 541 231 0 0 0 0 0 0 0 0 0
Totale 38.962